Flip-flop HSV-BAC: Bacterial artificial chromosome based system for rapid generation of recombinant herpes simplex virus vectors using two independent site-specific recombinases

BMC Biotechnology

Volumn 6, Issue , 2006, Pages

  Kuroda, Toshihiko ^a   Martuza, Robert L ^a   Todo, Tomoki ^a,b   Rabkin, Samuel D ^a  

^a MASSACHUSETTS GENERAL HOSPITAL   (United States)

^b UNIVERSITY OF TOKYO   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

BACTERIAL ARTIFICIAL CHROMOSOME; HERPES SIMPLEX VIRUS (HSV); RECOMBINANT VIRUS; TUMOR CELLS;

BACTERIA; CELLS; DISEASES; SKIN; TUMORS; VIRUSES;

BIOTECHNOLOGY;

CRE RECOMBINASE; INFECTED CELL PROTEIN 4; ONCOLYTIC VIRUS; RECOMBINASE; UNCLASSIFIED DRUG; VIRUS PROTEIN; VIRUS VECTOR;

ANIMAL CELL; ARTICLE; BACTERIAL ARTIFICIAL CHROMOSOME; CONTROLLED STUDY; DELETION MUTANT; DNA PACKAGING; GENE CASSETTE; GENE EXPRESSION; GENE INSERTION; GENE SEQUENCE; GENE TARGETING; GENETIC TRANSCRIPTION; GENOME SIZE; HERPES SIMPLEX VIRUS; HUMAN; HUMAN CELL; ISOLATION PROCEDURE; NONHUMAN; PLASMID; PROMOTER REGION; TRANSGENE; VIROGENESIS; VIRUS PURIFICATION; VIRUS RECOMBINANT; VIRUS REPLICATION;

CHROMOSOMES, ARTIFICIAL, BACTERIAL; CLONING, MOLECULAR; GENETIC VECTORS; ONCOLYTIC VIRUSES; RECOMBINASES; SIMPLEXVIRUS;

BACTERIA (MICROORGANISMS); SIMPLEXVIRUS;

EID: 33750074397     PISSN: 14726750     EISSN: 14726750     Source Type: Journal    
DOI: 10.1186/1472-6750-6-40     Document Type: Article

References (50)

1. Aghi M, Martuza RL: Oncolytic viral therapies - the clinical experience. Oncogene 2005, 24:7802-7816.
2. Martuza RL, Malick A, Markert JM, Ruffner KL, Coen DM: Experimental therapy of human giloma by means of a genetically engineered virus mutant. Science 1991, 252:854-856.
3. Parker JN, Gillespie GY, Love CE, Randall S, Whitley RJ, Markert JM: Engineered herpes simplex virus expressing IL-12 in the treatment of experimental murine brain tumors. Proc Natl Acad Sci U S A 2000, 97:2208-2213.
4. Miyatake S, Iyer A, Martuza RL, Rabkin SD: Transcriptional targeting of herpes simplex virus for cell-specific replication. J Virol 1997, 71:5124-5132.
5. Stavropoulos TA, Strathdee CA: An enhanced packaging system for helper-dependent herpes simplex virus vectors. J Virol 1998, 72:7137-7143.
6. Horsburgh BC, Hubinette MM, Qiang D, MacDonald ML, Tufaro F. Allele replacement: an application that permits rapid manipulation of herpes simplex virus type I genomes. Gene Ther 1999, 6:922-930.
7. Saeli Y, Ichikawa T, Saeki A, Chiocca EA, Tobler K, Ackermann M, Breakefield XO, Fraefel C: Herpes simplex virus type I DNA amplified as bacterial artificial chromosome in Escherichia coli: rescue of replication-competent virus progeny and packaging of amplicon vectors. Hum Gene Ther 1998, 9:2787-2794.
8. Tanaka M, Kagawa H, Yamanashi Y, Sata T, Kawaguchi Y: Construction of an excisable bacterial artificial chromosome containing a full-length infectious clone of herpes simplex virus type I: viruses reconstituted from the clone exhibit wild-type properties in vitro and in vivo. J Virol 2003, 77:1382-1391.
9. Adler H, Messerle M, Wagner M, Koszinowski UH: Cloning and mutagenesis of the murine gammaherpesvirus 68 genome as an infectious bacterial artificial chromosome. J Virol 2000, 74:6964-6974.
10. Hahn G, Khan H, Baldanti F, Koszinowski UH, Revello MG, Gerna G: The human cytomegalovirus ribonucleotide reductase homolog UL45 is dispensable for growth in endothelial cells, as determined by a BAC-cloned clinical isolate of human cytomegalovirus with preserved wild-type characteristics. J Virol 2002, 76:9551-9555.
11. Smith GA, Enquist LW: Construction and transposon mutagenesis in Escherichia coli of a full-length infectious clone of pseudorabies virus, an alphaherpesvirus. J Virol 1999, 73:6405-6414.
12. Strathdee CA: Transposing BACs to the future. Nat Biotechnol 1999, 17:332-333.
13. Schumacher D, Tischer BK, Fuchs W, Osterrieder N: Reconstitution of Marek's disease virus serotype 1 (MDV-1) from DNA cloned as a bacterial artificial chromosome and characterization of a glycoprotein B-negative B-negative MDV-I mutant. J Virol 2000, 74:11088-11098.
14. Messerle M, Crnkovic I, Hammerschmidt W, Ziegler H, Koszinowski UH: Cloning and mutagenesis of a herpesvirus genome as an infectious bacterial artificial chromosome. Proc Natl Acad Sci U S A 1997, 94:14759-14763.
15. Domi A, Moss B: Engineering of a vaccinia virus bacterial artificial chromosome in Escherichia coli by bacteriophage lambda-based recombination. Nat Methods 2005, 2:95-97.
16. White RE, Calderwood MA, Whitehouse A: Generation and precise modification of a herpesvirus saimiri bacterial artificial chromosome demonstrates that the terminal repeats are required for both virus production and episomal persistence. J Gen Virol 2003, 84:3393-3403.
17. Wade-Martins R, Saeki Y, Chiocca EA: Infectious delivery of a 135-kb LDLR genomic locus leads to regulated complementation of low-density lipoprotein receptor deficiency in human cells. Mol Ther 2003, 7:604-612.
18. Wade-Martins R, Smith ER, Tyminski E, Chiocca EA, Saeki Y: An infectious transfer and expression system for genomic DNA loci in human and mouse cells. Nat Biotechnol 2001, 19:1067-1070.
19. Shizuya H, Birren B, Kim UJ, Mancino V, Slepak T, Tachiiri Y, Simon M: Cloning and stable maintenance of 300-kilobase-pair fragments of human DNA in Escherichia coil using an F-factor-based vector. Proc Natl Acad Sci U S A 1992, 89:8794-8797.
20. Adler H, Messerle M, Koszinowski UH: Virus reconstituted from infectious bacterial artificial chromosome (BAC)-cloned murine gammaherpesvirus 68 acquires wild-type properties in vivo only after excision of BAC vector sequences. J Virol 2001, 75:5692-5696.
21. Smith GA, Enquist LW: A self-recombining bacterial artificial chromosome and its application for analysis of herpesvirus pathogenesis. Proc Natl Acad Sci U S A 2000, 97:4873-4878.
22. DeLuca NA, McCarthy AM, Schaffer PA: Isolation a characterization of deletion mutants of herpes simplex virus type I in the gene encoding immediate-early regulatory protein ICP4. J Virol 1985, 56:558-570.
23. Weir JP: Regulation of herpes simplex virus gene expression. Gene 2001, 271:117-130.
24. Miyatake SI, Tani S, Feigenbaum F, Sundaresan P, Toda H, Narumi O, Kikuchi H, Hashimoto N, Hangai M, Martuza RL, Rabkin SD: Hepatoma-specific antitumor activity of an albumin enhancer/promoter regulated herpes simplex virus in vivo. Gene Ther 1999, 6:564-572.
25. Yamamura H, Hashio M, Noguchi M, Sugenoya Y, Osakada M, Hirano N, Sasaki Y, Yoden T, Awata N, Araki N, Tatsuta M, Miyatake SI, Takahashi K: Identification of the transcriptional regulatory sequences of human calponin promoter and their use in targeting a conditionally replicating herpes vector to malignant human soft tissue and bone tumors. Cancer Res 2001, 61:3969-3977.
26. Goldstein DJ, Weller SK: Factor(s) present in herpes simplex virus type I-infected cells can compensate for the loss of the large subunit of the viral ribonucleotide reductase: characterization of an ICP6 deletion mutant. Virology 1988, 166:41-51.
27. Mineta T, Rabkin SD, Yazaki T, Hunter WD, Martuza RL: Attenuated. multi-mutated herpes simplex virus-1 for the treatment of malignant gliomas. Nat Med 1995, 1:938-943.
28. Yoon SS, Nakamura H, Carroll NM, Bode BP, Chiocca EA, Tanabe KK: An oncolytic herpes simplex virus type I selectively destroys diffuse liver metastases, from colon carcinoma. Faseb J 2000, 14:301-311.
29. Kaname T, Huxley C: Simple and efficient vectors for retrofitting BACs and PACs with mammalian neoR and EGFP marker genes. Gene 2001, 266:147-153.
30. DeWeese TL. van der Poel H. Li S. Mikhak B. Drew R. Goemann M. Hamper U, DeJong R, Detorie N, Rodrigućez R, Haulk T, DeMarzo AM, Piantadosi S, Yu DC, Chen Y, Henderson DP, Carducci MA, Nelson WG, Simons JW: A phase I trial of CV706, a replication-competent, PSA selective oncolytic adenovirus, for the treatment of locally recurrent prostate cancer following radiation therapy. Cancer Res 2001, 61:7464-7472.
31. Ko D, Hawkins L, Yu DC: Development of transcriptionally regulated oncolytic adenoviruses Oncogene 2005 24:7763-7774.
32. Kambara H, Okano H, Chiocca EA Saeki Y: An oncolytic HSV-1 mutant expressing ICP34.5 under control of a nestin promoter increases survival of animals even when symptomatic from a brain tumor. Cancer Res 2005, 65:2832-2839.
33. Fukuhara H, Ino Y, Kuroda T, Martuza RL, Todo T: Triple gene-deleted oncolytic herpes simplex virus vector double-armed with interleuldn 18 and soluble B7-1 constructed by bacterial artificial chromosome-mediated system. Cancer Res 2005, 65:10663-10668.
34. Terada K, Wakimoto H, Tyminski E, Chiocca EA, Saeki Y: Development of a rapid method to generate multiple oncolytic HSV vectors and their in vivo evaluation using syngeneic mouse tumor models. Gene Ther 2006, 13:705-714.
35. Saeki Y, Fraefel C, Ichikawa T, Breakefield XO, Chiocca EA: Improved helper virus-free packaging system for HSV amplicon vectors using an ICP27-deleted, oversized HSV-1 DNA in a bacterial artificial chromosome. Mol Ther 2001, 3:591-601.
36. Gaudreau A, Hill E, Balfour HHJ, Erice A, Boivin G: Phenotypic and genotypic characterization of acyclovir-resistant herpes simplex viruses from immunocompromised patients. J Infect Dis 1998, 178:297-303.
37. Mineta T, Rabkin SD, Martuza RL: Treatment of malignant gliomas using ganciclovir-hypersensitive, ribonucleotide reductase-deficient herpes simplex viral mutant. Cancer Res 1994, 54:3963-3966.
38. Coen DM, Goldstein DJ, Weller SK: Herpes simplex virus ribonucleotide reductase mutants are hypersensitive to acyclovir. Andmicrob Agents Chemother 1989, 33:1395-1399.
39. Stinski MF, Roehr TJ: Activation of the major Immediate early gene of human cytomegalovirus by cis-acting elements in the promoter-regulatory sequence and by virus-specific transacting components. J Virol 1985, 55:431-44
40. Samaniego LA, Neiderhiser L, DeLuca NA: Persistence and expression of the herpes simplex virus genome in the absence of immediate-early proteins. J Virol 1998, 72:3307-3320.
41. Preston CM, Nicholl MJ: Repression of gene expression upon infection of cells with herpes simplex virus type I mutants impaired for imniediate-early protein synthesis. J Virol 1997, 71:7807-7813.
42. Kuroda T, Rabkin SD, Martuza RL: Effective treatment of tumors with strong beta-catenin/Tcf activity by transcriptionally targeted oncolytic herpes simplex virus vector. Cancer Res in press.
43. Addison CL, Hitt M, Kunsken D, Graham FL: Comparison of the human versus murine cytomegalovirus immediate early gene promoters for transgene expression by adenoviral vectors. J Gen Virol 1997, 78 (Pt 7):1653-1661.
44. Baskar JF, Smith PP, Nilaver G, Jupp RA, Hoffmann S, Peffer NJ, Tenney DJ, Colberg-Poley AM, Ghazal P, Nelson JA: The enhancer domain of the human cytomegalovirus major immediate-early promoter determines cell type-specific expression in transgenic mice. J Virol 1996, 70:3207-3214.
45. Foecking MK, Hofstetter H: Powerful and versatile enhancerpromoter unit for mammalian expression vectors. Gene 1986,45:101-105.
46. Furth PA, Hennighausen L, Baker C, Beatty B, Woychick R: The variability in activity of the universally expressed human cytomegalovirus immediate early gene 1 enhancer/promoter in transgenic mice. Nucleic Acids Res 1991, 19:6205-6208.
47. Goldstein DJ, Weller SK: Herpes simplex virus type I-induced ribonucleotide reductase activity is dispensable for virus growth and DNA synthesis: isolation and characterization of an ICP6 lacZ insertion mutant. J Virol 1988,62:196-205.
48. Umana P, Gerdes CA, Stone D, Davis JR, Ward D, Castro MG, Lowenstein PR: Efficient FLPe recombinase enables scalable production of helper-dependent adenoviral vectors with negligible helper-virus contamination. Nat Biotechnol 2001, 19:582-585.
49. Walboomers JM, Schegget JT: A new method for the isolation of herpes simplex virus type 2 DNA. Virology 1976, 74:256-258.
50. Kintner RL, Brandt CR: Rapid small-scale isolation of herpes simplex virus DNA. J Virol Methods 1994, 48:189-196.